Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) highlighted an article (Dec 29, 2025) summarizing initial proof‑of‑concept results for crofelemer in pediatric intestinal failure patients in the UAE.
Key findings: parenteral support (PS) reductions ranged 12–37%—two SBS-IF patients showed 12.5–15.6% PS reduction at the highest dose over 12 weeks; one MVID patient showed up to 27% reduction over 12 weeks and up to 37% during an extension after reinitiation. Results also reported reduced loose watery stools.
The company notes PS has serious toxicities and crofelemer’s PS reductions may be disease‑modifying. Crofelemer holds Orphan Drug Designation from FDA and EMA; additional placebo‑controlled trials and an FDA meeting regarding an expedited pathway were also reported.
Jaguar Health (NASDAQ:JAGX) announced it received a $240,000 grant from the FDA Center for Veterinary Medicine on January 1, 2026 to support its Canalevia-CA1 effectiveness study for chemotherapy-induced diarrhea (CID) in dogs.
Canalevia-CA1 is conditionally approved for CID and the FDA renewed that conditional approval for a fifth and final year through December 21, 2026. Jaguar must complete and file a successful effectiveness study to obtain full veterinary drug approval for CID.
Jaguar Health (NASDAQ:JAGX) said an independent investigator submitted an abstract reporting preliminary clinical findings for a novel oral liquid formulation of crofelemer in adult short bowel syndrome with intestinal failure (SBS-IF); the abstract was submitted for consideration at Digestive Disease Week® May 2-5, 2026.
The release highlights prior independent trial results: crofelemer reduced parenteral support (PS) by 12–15.6% in two pediatric SBS-IF patients over 12 weeks, and by up to 27% (and up to 37% on extension) in an initial MVID patient. Jaguar completed an FDA meeting in October 2025 on a possible expedited pathway for MVID. Crofelemer holds Orphan Drug Designation in the US and EU for SBS and MVID.
Jaguar Health (NASDAQ:JAGX) announced the FDA renewed the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs, effective through December 21, 2026. The company said this renewal represents the fifth and final allowable year of conditional approval.
A confirmatory effectiveness trial is underway and is expected to conclude in February 2026, ahead of the FDA's June deadline; the study has enrolled 51 dogs to date with approximately 49 more expected. Canalevia-CA1 is available from multiple leading U.S. veterinary distributors, including Chewy.
Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all three proposals at the Special Meeting held on December 8, 2025. The company highlighted early clinical and regulatory developments for crofelemer in microvillus inclusion disease (MVID): an investigator-initiated proof-of-concept trial showed crofelemer may extend infant lives and reduce total parenteral support (PS) volumes by up to 37%, though the report notes associated toxicity. Jaguar completed a meeting with the FDA on October 2, 2025 to seek advice on advancing its placebo-controlled crofelemer trial toward a possible expedited approval pathway. CEO Lisa Conte will present updates on December 10, 2025, 3:25–3:35 PM ET at the Emerging Growth Conference.
Jaguar Health (NASDAQ:JAGX) said its Italian unit submitted a request to the European Medicines Agency for CVMP scientific advice on pursuing EU approval of Canalevia (crofelemer) for general diarrhea in dogs based on a 2017 study of 200 dogs. The CVMP review is requested for its March 2026 meeting; EMA will have 60 days (extendable to 90) to respond. If EMA agrees the updated analysis supports approval, Jaguar would file a Marketing Authorization Application to sell Canalevia across the 27 EU member states. Jaguar also noted FDA conditional approval for chemotherapy-induced diarrhea in dogs and cited EU/US dog population and case estimates.
Jaguar Health (NASDAQ:JAGX) announced an Australian patent issued to Napo for methods treating short bowel syndrome (SBS), bile acid diarrhea, and post-resection diarrhea using an inhibitor of chloride-ion transport such as crofelemer (Nov 24, 2025).
Jaguar cited emerging proof-of-concept clinical data: two pediatric SBS-IF patients showed 12.5–15.6% reduction in parenteral support (PS) at 12 weeks; one MVID patient showed up to 27% reduction at 12 weeks and up to 37% on extension. Ongoing randomized trials and expanded access programs are active in US, EU, Middle East.
Jaguar Health (NASDAQ:JAGX) said Napo Pharmaceuticals submitted an amended protocol to the FDA on November 20, 2025 to support a possible expedited approval pathway for crofelemer to treat intestinal failure in pediatric patients with microvillus inclusion disease (MVID).
Company cites investigator-initiated trial data showing parenteral support (PS) reductions of 12–37% in pediatric intestinal failure patients and up to 27%–37% PS reduction in the initial MVID patient. Jaguar also discussed potential review with the EMA and is supplying crofelemer for two U.S. expanded access programs.
Jaguar Health (NASDAQ: JAGX) reported Q3 2025 net revenue of ~$3.1M, up ~4% versus Q2 2025, with Mytesi prescription volume up ~0.9% sequentially but down ~3.6% year-over-year. The company recorded a net loss attributable to common stockholders of $9.5M and non-GAAP recurring EBITDA of -$8.9M. License revenue of $42,858 was recognized and deferred contract revenue totaled ~ $595k as of September 30, 2025.
Clinical update: investigator-initiated proof-of-concept data suggest crofelemer may extend survival and reduce parenteral support volume by up to 37% in infants with MVID, though associated toxicity was reported. Jaguar met with the FDA on October 2, 2025 to discuss an expedited approval pathway for a placebo-controlled crofelemer trial.
Jaguar Health (NASDAQ:JAGX) announced it will file its Form 10-Q for the quarter ended September 30, 2025 on November 14, 2025 and will host an investor webcast to review Q3 2025 financials and corporate updates.
The webcast is scheduled for Monday, November 17, 2025 at 8:30 AM Eastern. Registration and participant access are available via the company’s registration link.